<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Physiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Physiol</journal-id><journal-id journal-id-type="publisher-id">Front. Physiol.</journal-id><journal-title-group><journal-title>Frontiers in Physiology</journal-title></journal-title-group><issn pub-type="epub">1664-042X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26300782</article-id><article-id pub-id-type="pmc">4528259</article-id><article-id pub-id-type="doi">10.3389/fphys.2015.00216</article-id><article-categories><subj-group subj-group-type="heading"><subject>Physiology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Xylooligosaccharide supplementation alters gut bacteria in both healthy and prediabetic adults: a pilot study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jieping</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/231064/overview"/></contrib><contrib contrib-type="author"><name><surname>Summanen</surname><given-names>Paula H.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Henning</surname><given-names>Susanne M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/245039/overview"/></contrib><contrib contrib-type="author"><name><surname>Hsu</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/233293/overview"/></contrib><contrib contrib-type="author"><name><surname>Lam</surname><given-names>Heiman</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/260716/overview"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Jianjun</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tseng</surname><given-names>Chi-Hong</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dowd</surname><given-names>Scot E.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/47410/overview"/></contrib><contrib contrib-type="author"><name><surname>Finegold</surname><given-names>Sydney M.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/98675/overview"/></contrib><contrib contrib-type="author"><name><surname>Heber</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhaoping</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/191642/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Center for Human Nutrition, David Geffen School of Medicine, University of California, Los Angeles</institution><country>Los Angeles, CA, USA</country></aff><aff id="aff2"><sup>2</sup><institution>Infectious Diseases Section, VA West Los Angeles Medical Center</institution><country>Los Angeles, CA, USA</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Statistics Core, David Geffen School of Medicine, University of California Los Angeles</institution><country>Los Angeles, CA, USA</country></aff><aff id="aff4"><sup>4</sup><institution>MR DNA Molecular Research LP</institution><country>Shallowwater, TX, USA</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles</institution><country>Los Angeles, CA, USA</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Ghanshyam Upadhyay, The City College of New York - CUNY, USA</p></fn><fn fn-type="edited-by"><p>Reviewed by: Cristina M. Sena, University Coimbra, Portugal; Maria Ines Vaccaro, University of Buenos Aires&#x02014;CONICET, Argentina</p></fn><corresp id="fn001">*Correspondence: Zhaoping Li, Center for Human Nutrition, David Geffen School of Medicine, University of California, Los Angeles, 900 Veteran Avenue, Warren Hall 12-217, Los Angeles, CA 90095, USA <email xlink:type="simple">zli@mednet.ucla.edu</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Gastrointestinal Sciences, a section of the journal Frontiers in Physiology</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>6</volume><elocation-id>216</elocation-id><history><date date-type="received"><day>21</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>17</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Yang, Summanen, Henning, Hsu, Lam, Huang, Tseng, Dowd, Finegold, Heber and Li.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Yang, Summanen, Henning, Hsu, Lam, Huang, Tseng, Dowd, Finegold, Heber and Li</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><bold>Background:</bold> It has been suggested that gut microbiota is altered in Type 2 Diabetes Mellitus (T2DM) patients.</p><p><bold>Objective:</bold> This study was to evaluate the effect of the prebiotic xylooligosaccharide (XOS) on the gut microbiota in both healthy and prediabetic (Pre-DM) subjects, as well as impaired glucose tolerance (IGT) in Pre-DM.</p><p><bold>Subjects/Methods:</bold> Pre-DM (<italic>n</italic> = 13) or healthy (<italic>n</italic> = 16) subjects were randomized to receive 2 g/day XOS or placebo for 8-weeks. In Pre-DM subjects, body composition and oral glucose tolerance test (OGTT) was done at baseline and week 8. Stool from Pre-DM and healthy subjects at baseline and week 8 was analyzed for gut microbiota characterization using Illumina MiSeq sequencing.</p><p><bold>Results:</bold> We identified 40 Pre-DM associated bacterial taxa. Among them, the abundance of the genera <italic>Enterorhabdus, Howardella</italic>, and <italic>Slackia</italic> was higher in Pre-DM. XOS significantly decreased or reversed the increase in abundance of <italic>Howardella, Enterorhabdus</italic>, and <italic>Slackia</italic> observed in healthy or Pre-DM subjects. Abundance of the species <italic>Blautia hydrogenotrophica</italic> was lower in pre-DM subjects, while XOS increased its abundance. In Pre-DM, XOS showed a tendency to reduce OGTT 2-h insulin levels (<italic>P</italic> = 0.13), but had no effect on body composition, HOMA-IR, serum glucose, triglyceride, satiety hormones, and TNF&#x003b1;.</p><p><bold>Conclusion:</bold> This is the first clinical observation of modifications of the gut microbiota by XOS in both healthy and Pre-DM subjects in a pilot study. Prebiotic XOS may be beneficial in reversing changes in the gut microbiota during the development of diabetes.</p><p><bold>Clinical trial registration:</bold> NCT01944904 (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01944904">https://clinicaltrials.gov/ct2/show/NCT01944904</ext-link>).</p></abstract><kwd-group><kwd>xylooligosaccharide</kwd><kwd>prediabetic</kwd><kwd>diabetes</kwd><kwd>gut</kwd><kwd>microbiota</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Center for Human Nutrition, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles</funding-source></award-group></funding-group><counts><fig-count count="6"/><table-count count="1"/><equation-count count="0"/><ref-count count="40"/><page-count count="11"/><word-count count="5880"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Increasing evidence indicates that changes in gut microbiota composition might contribute to the development of metabolic disorders such as obesity and T2DM (Qin et al., <xref rid="B31" ref-type="bibr">2012</xref>). Several mechanisms have been proposed regarding how gut bacteria could facilitate the pathogenesis of T2DM (Shen et al., <xref rid="B35" ref-type="bibr">2013</xref>). Studies suggest that gut bacteria influence whole-body metabolism through regulation of the host's immune response, energy extraction and utilization, intestinal glucose absorption, and lipid metabolism (Musso et al., <xref rid="B28" ref-type="bibr">2011</xref>). The central feature of obesity and T2DM is insulin resistance, potentially caused by low-grade inflammation resulting from nutrient excess and leading to endoplasmic reticulum (ER) stress. More and more research has shown that gut microbiota is another important factor for this low-grade inflammation (Chassaing and Gewirtz, <xref rid="B9" ref-type="bibr">2014</xref>). The <italic>Bacteroidetes</italic>/<italic>Firmicutes</italic> ratio is associated with increased plasma glucose concentrations and a decrease in butyrate-producing bacteria in T2DM patients (Larsen et al., <xref rid="B25" ref-type="bibr">2010</xref>; Shen et al., <xref rid="B35" ref-type="bibr">2013</xref>). Recent studies in mice have demonstrated that an increase in the abundance of <italic>Bifidobacteria</italic> and <italic>Akkermansia muciniphila</italic> attenuated high fat diet-induced metabolic complications (Everard et al., <xref rid="B15" ref-type="bibr">2013</xref>).</p><p>Pre-DM refers to the intermediate stage between normoglycemia and overt diabetes mellitus. Pre-DM is characterized by glucose dysregulation and a higher risk of developing T2DM and other associated complications (Portero McLellan et al., <xref rid="B30" ref-type="bibr">2014</xref>). However, not all individuals with Pre-DM progress to overt T2DM. With changes in lifestyle and diet, the progression of Pre-DM to T2DM can be prevented or delayed (Portero McLellan et al., <xref rid="B30" ref-type="bibr">2014</xref>). Given the significant involvement of certain gut bacteria in host metabolism (Shen et al., <xref rid="B35" ref-type="bibr">2013</xref>), therapeutic manipulation of the gut microbiota has been proposed for both individuals with T2DM and in those at risk of developing the condition.</p><p>Prebiotics are highly effective and important for many applications in medicine. They are not digestible and do not contribute to human nourishment, but rather exert a profound effect on the human gut microbiota (International Scientific Association for Probiotics and Prebiotics, <xref rid="B21" ref-type="bibr">2004</xref>). Prebiotic-induced modulation of gut microbiota has been developed and widely used (Everard et al., <xref rid="B16" ref-type="bibr">2011</xref>). The principal effect of prebiotics on the human gut microbiota is to stimulate the growth of the <italic>Bifidobacterium</italic> and <italic>Lactobacillus</italic> genera (Marotti et al., <xref rid="B26" ref-type="bibr">2012</xref>). Prebiotic treatment is known to modulate host gene expression and metabolism as well (Everard et al., <xref rid="B16" ref-type="bibr">2011</xref>). Dietary intervention using prebiotic inulin or oligofructose (FOS) alters the gut microflora composition by promoting the growth of beneficial bacteria such as <italic>Bifidobacterium, Lactobacillus</italic>, and <italic>A. muciniphila</italic> (Rossi et al., <xref rid="B34" ref-type="bibr">2005</xref>; Choi and Shin, <xref rid="B10" ref-type="bibr">2006</xref>). However, the mechanisms associating prebiotics and its beneficial effects have yet to be fully understood. Further studies are needed to examine the precise physiological roles of prebiotics on human bowel flora and in host immune function.</p><p>Xylooligosaccharide (XOS) is a recent prebiotic that can be incorporated into many food products (Aachary and Prapulla, <xref rid="B1" ref-type="bibr">2011</xref>). Our lab previously reported that XOS, at the dose of 2.8 g/day, was well tolerated, and modified the gut bacterial composition in healthy people (Finegold et al., <xref rid="B17" ref-type="bibr">2014</xref>). A consideration of the gut microbiota in the context of health benefits of XOS in Pre-DM is especially relevant since recent research has indicated a critical role of gut microbiota in the development of T2DM (Qin et al., <xref rid="B31" ref-type="bibr">2012</xref>). The present study was designed to determine the effect of XOS supplementation on the gut microbiota in healthy and pre-DM individuals. Since the ultimate objective of this research is to explore the potential effects of XOS in the prevention of progression of Pre-DM to T2DM, we also evaluated the effects of XOS in the management of IGT, body composition, and inflammatory marker in Pre-DM subjects.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and methods</title><sec><title>Subjects</title><p>This was a double-blind, randomized, placebo-controlled study with 34 subjects who were recruited based on inclusion and exclusion criteria. The study population consisted of 16 healthy subjects (placebo: <italic>n</italic> = 9; XOS: <italic>n</italic> = 7) and 13 Pre-DM subjects (placebo: <italic>n</italic> = 6; XOS: <italic>n</italic> = 7).</p></sec><sec><title>Ethics</title><p>The study was carried out in accordance with the guidelines of the Office for Protection of Research Subjects of the University of California, Los Angeles and the Institutional Review Board of the VA Greater LA Health Center. All subjects provided written informed consent before the study began.</p></sec><sec><title>Study design</title><p>The enrollment criteria for healthy participants was fasting plasma glucose of 65&#x02013;100 mg/dl, Participants in the Pre-DM study were selected based on the American Diabetes Association criteria for impaired fasting glucose (fasting plasma glucose of 100&#x02013;125 mg/dl) and/or HgbA1c (5.7&#x02013;6.4%) (American Diabetes Association, <xref rid="B5" ref-type="bibr">2014</xref>). Over the span of 8 weeks, both healthy and Pre-DM subjects were randomly assigned to take daily a capsule supplement containing either 2 g XOS (2.8 grams of 70% XOS) or placebo. The XOS and placebo were provided by Life Bridge International (Riverside, CA). The XOS was manufactured by Shandong Longlive Bio-Technology Co., Ltd., China. The placebo capsules contained maltodextrin. The study consisted of three phases: a 2-week run-in phase, and an 8-week intervention phase.</p></sec><sec><title>Stool collection</title><p>A total of two stools were collected from each subject: at baseline and week 8 of the intervention periods. Each time the entire stool specimen was obtained. The specimen was placed in a large, zip-lock freezer bag and all air was pushed out of the bag as the zip lock was closed. The specimen was delivered on ice to the UCLA Center for Human Nutrition within 24 h of collection where it was immediately stored at &#x02212;20&#x000b0;C.</p></sec><sec><title>Miseq sequencing</title><p>DNA from stool was extracted using a commercial extraction system (QIAamp Stool DNA Extraction Kit, Qiagen, Valencia, CA). The quality of the DNA samples was confirmed using a Bio-Rad Experion system (Bio-Rad Laboratories, CA, USA). The 16S rRNA gene V4 variable region PCR primers 515/806 with barcode on the forward primer were used in a 30 cycle PCR using the HotStarTaq Plus Master Mix Kit (Qiagen, USA) under the following conditions: 94&#x000b0;C for 3 min, followed by 28 cycles of 94&#x000b0;C for 30 s, 53&#x000b0;C for 40 s and 72&#x000b0;C for 1 min, after which a final elongation step at 72&#x000b0;C for 5 min was performed. After amplification, PCR products are checked in 2% agarose gel to determine the success of amplification and the relative intensity of bands. Sequencing was performed at MR DNA (<ext-link ext-link-type="uri" xlink:href="http://www.mrdnalab.com">www.mrdnalab.com</ext-link>, Shallowater, TX, USA) on a MiSeq following the manufacturer's guidelines. Sequence data were processed using a proprietary analysis pipeline (MR DNA, Shallowater, TX, USA). Operational taxonomic units (OTUs) were defined by clustering at 3% divergence (97% similarity). Final OTUs were taxonomically classified using BLASTn against a curated GreenGenes database (DeSantis et al., <xref rid="B12" ref-type="bibr">2006</xref>).</p></sec><sec><title>Body composition</title><p>Body composition was measured using the Tanita-BC418 bioelectrical impedance analyzer (Tanita Corp., Japan).</p></sec><sec><title>Glucose tolerance test</title><p>On the test days at baseline and week 8, Pre-DM subjects remained in a fasting state for 2.5 h prior to the beginning of OGTT. The 75 g glucose cola was administrated immediately after the basal blood draw at 0 min. Subsequent blood samples were taken 30, 60, and 120 min afterwards. Serum samples were kept at &#x02212;80&#x000b0;C. The insulin resistance index assessed by the homeostasis model (HOMA-IR) was calculated as follows (Allard et al., <xref rid="B2" ref-type="bibr">2003</xref>): (fasting blood glucose [mmol/l] &#x000d7; fasting plasma insulin [&#x003bc;U/ml])/22.5.</p></sec><sec><title>Blood biochemical analysis</title><p>Blood samples were collected and coded to protect patient confidentiality. Lipids, insulin, glucose, and satiety hormones were measured. Serum triglycerides were determined using a enzymatic method (Pointe Scientific, MI). Serum glucose was determined using Glucose Assay kit (Cayman Chemical Company, MI). Serum insulin, active GLP-1, leptin, pancreatic polypeptides (PP) and TNF&#x003b1; were determined using the MILLIPLEX map kit (EMD Millipore, Billerica, MA) and data were captured and processed using Luminext 200 with xPonent software.</p></sec><sec><title>Statistics</title><p>Demographic data at baseline were analyzed and presented as mean &#x000b1; SD and two sample <italic>t</italic>-tests were used for comparisons between the placebo and XOS groups. For analysis of serum variables, such as insulin, glucose, values of mean &#x000b1; SE at baseline and week 8 were presented for all groups, and two sample <italic>t</italic>-test was used to compare the two groups at baseline and 8 weeks. For DNA sequencing analyses, Wilcoxon rank sum test was utilized to evaluate the differences between study groups. All tests are two sided and all analyses were conducted using SAS 9.3 (Statistical Analysis System, Cary, NC, 2008) and R (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">www.r-project.org</ext-link>) software.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec><title>Subjects</title><p>The study population consisted of 16 healthy participants (4 men and 12 women) aged between 21 and 49 years, and 13 Pre-DM participants (9 men and 4 women) aged between 30 and 63. Participants did not report any adverse effects or symptoms with the XOS intervention at 2 g/day. Table <xref ref-type="table" rid="T1">1</xref> shows the baseline characteristics of the participants in the four groups. The composition of the fecal microbiome from all healthy participants and Pre-DM participants was analyzed by Miseq sequencing.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Baseline characteristics of the study participants</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><bold>Healthy placebo (<italic>n</italic> = 9)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Healthy XOS (<italic>n</italic> = 7)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Pre-DM placebo (<italic>n</italic> = 6)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Pre-DM XOS (<italic>n</italic> = 7)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, year</td><td valign="top" align="center" rowspan="1" colspan="1">31.9 &#x000b1; 6.9</td><td valign="top" align="center" rowspan="1" colspan="1">31.7 &#x000b1; 9.3</td><td valign="top" align="center" rowspan="1" colspan="1">44.8 &#x000b1; 11.2</td><td valign="top" align="center" rowspan="1" colspan="1">55.0 &#x000b1; 6.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Weight, kg</td><td valign="top" align="center" rowspan="1" colspan="1">65.4 &#x000b1; 14.0</td><td valign="top" align="center" rowspan="1" colspan="1">69.9 &#x000b1; 13.0</td><td valign="top" align="center" rowspan="1" colspan="1">94.9 &#x000b1; 15.9</td><td valign="top" align="center" rowspan="1" colspan="1">97.4 &#x000b1; 22.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup></td><td valign="top" align="center" rowspan="1" colspan="1">23.4 &#x000b1; 3.2</td><td valign="top" align="center" rowspan="1" colspan="1">25.6 &#x000b1; 3.2</td><td valign="top" align="center" rowspan="1" colspan="1">33.6 &#x000b1; 7.2</td><td valign="top" align="center" rowspan="1" colspan="1">32.2 &#x000b1; 4.2</td></tr></tbody></table><table-wrap-foot><p><italic>Values are presented as mean &#x000b1; standard deviation (SD). For all characteristics, there were no significant differences between the placebo and XOS groups (all P &#x0003e; 0.05, based on independent sample t-tests). BMI, body mass index</italic>.</p></table-wrap-foot></table-wrap></sec><sec><title>Gut microbial composition changes related to Pre-DM</title><p>Miseq sequencing was used to compare the gut microbial composition of baseline samples from 16 healthy and 13 Pre-DM subjects. The abundance (percentage of total sequences) of 1 phylum, 1 class, 3 families, 13 genera, and 22 species, was significantly different between healthy and Pre-DM (Supplementary Table <xref ref-type="supplementary-material" rid="SM1">1</xref>). Composition of phyla in healthy and Pre-DM groups is displayed in Figure <xref ref-type="fig" rid="F1">1A</xref>. The abundance of infectious and T2DM related phylum <italic>Synergistetes</italic> (Baumgartner et al., <xref rid="B6" ref-type="bibr">2012</xref>; Qin et al., <xref rid="B31" ref-type="bibr">2012</xref>) was significantly higher in Pre-DM compared with healthy subjects (<italic>P</italic>&#x02264;0.05) <xref ref-type="fig" rid="F1">(Figure 1A</xref>). In addition, 13 genera responded significantly in Pre-DM (<italic>P</italic>&#x02264;0.05) (Figure <xref ref-type="fig" rid="F1">1B</xref>). The abundances of <italic>Allisonella, Cloacibacillus, Enterorhabdus, Howardella, Megamonas</italic>, and <italic>Slackia</italic> were significantly higher, while <italic>Adlercreutzia, Anaerococcus, Ethanoligenens, Gordonibacter, Lactococcus, Parasutterella</italic>, and <italic>Tissierella</italic> were greatly reduced in Pre-DM compared with healthy subjects (Figure <xref ref-type="fig" rid="F1">1B</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Comparison of gut microbiota composition between healthy (<italic>n</italic> = 16) and Pre-DM (<italic>n</italic> = 13) subjects. (A)</bold> Pie charts depict mean abundance (% of total) of the indicated phyla. <bold>(B)</bold> Bar graph of genera shows significant differences in abundance between healthy and Pre-DM subjects. Values are presented as mean &#x000b1; standard error (SE) <sup>*</sup><italic>P</italic> &#x02264; 0.05.</p></caption><graphic xlink:href="fphys-06-00216-g0001"/></fig></sec><sec><title>Effects of XOS supplementation on the gut microbiota in healthy and Pre-DM subjects</title><p>The overall changes of bacterial composition with 8-week XOS intervention were assessed at the phylum and genus levels (Figures <xref ref-type="fig" rid="F2">2</xref>, <xref ref-type="fig" rid="F3">3</xref>). Significant XOS-induced changes were found for 1 phyla, 3 classes, 7 families, 23 genera, and 25 species in healthy subjects (Figure <xref ref-type="fig" rid="F2">2</xref> and Supplementary Table <xref ref-type="supplementary-material" rid="SM1">2</xref>), and 3 classes, 1 families, 7 genera, and 17 species in Pre-DM subjects (Figure <xref ref-type="fig" rid="F3">3</xref> and Supplementary Table <xref ref-type="supplementary-material" rid="SM1">3</xref>). The mean abundance of indicated phyla of healthy subjects in placebo and XOS groups at baseline and week 8 are displayed in Figure <xref ref-type="fig" rid="F2">2A</xref>. The phylum <italic>Firmicutes</italic> showed a 20% increase in abundance over 8 weeks in placebo groups of healthy subjects, while XOS intervention significantly reversed this increase (<italic>P</italic> &#x02264; 0.05) (Figure <xref ref-type="fig" rid="F2">2A</xref>). The mean abundance of <italic>Verrucomicrobia</italic> increased in XOS groups of healthy subjects as well. Among genera with an average abundance &#x0003e;1% in at least one group, six were significantly regulated by XOS. An increase of infectious disease related <italic>Streptococcus</italic> and <italic>Subdoligranulum</italic> in placebo groups was largely inhibited by XOS in healthy subjects (Figure <xref ref-type="fig" rid="F2">2B</xref>). The 8-week XOS intervention did not induce significant changes of gut microbiota at the phylum level in Pre-DM subjects (Figure <xref ref-type="fig" rid="F3">3A</xref>). At the genus level, <italic>Blautia, Anaerotruncus, Dialister</italic>, and <italic>Oscillospira</italic> were four abundant genera identified with significant XOS-induced changes in Pre-DM subjects. XOS diminished or reversed the magnitude of population decline in all four genera (Figure <xref ref-type="fig" rid="F3">3B</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Effects of XOS supplementation on gut microbiota in healthy subjects (<italic>n</italic> = 16). (A)</bold> Pie charts display the mean abundance of indicated phyla of healthy subjects receiving placebo (<italic>n</italic> = 9) and XOS (<italic>n</italic> = 7) at baseline and week 8. <bold>(B)</bold> Bar graph of genera shows significant difference in abundance between placebo and XOS groups. Values are presented as mean &#x000b1; standard error (SE) <sup>*</sup><italic>P</italic> &#x02264; 0.05.</p></caption><graphic xlink:href="fphys-06-00216-g0002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Effects of XOS supplementation on gut microbiota in Pre-DM subjects (<italic>n</italic> = 13). (A)</bold> Pie charts display the mean abundance of indicated phyla of Pre-DM subjects receiving placebo (<italic>n</italic> = 6) and XOS (<italic>n</italic> = 7) at baseline and week 8. <bold>(B)</bold> Bar graph of genera shows significant difference in abundance between placebo and XOS groups. Values are presented as mean &#x000b1; standard error (SE) <sup>*</sup><italic>P</italic> &#x02264; 0.05.</p></caption><graphic xlink:href="fphys-06-00216-g0003"/></fig></sec><sec><title>XOS supplementation reversed gut bacterial alterations associated with Pre-DM</title><p>Of the 40 Pre-DM associated bacterial taxa (Supplementary Table <xref ref-type="supplementary-material" rid="SM1">1</xref>) identified in this study, the abundances of the <italic>Enterorhabdus, Howardella</italic>, and <italic>Slackia</italic> genera were elevated in Pre-DM. The 8-week XOS intervention significantly diminished or reversed the abundance increase of <italic>Howardella</italic> and <italic>Slackia</italic> observed in the placebo group of healthy subjects, as well as <italic>Enterorhabdus</italic> in Pre-DM subjects (Figures <xref ref-type="fig" rid="F4">4A&#x02013;C</xref>). <italic>B. hydrogenotrophica</italic> was less abundant in Pre-DM subjects (Supplementary Table <xref ref-type="supplementary-material" rid="SM1">1</xref>), but XOS intervention significantly reversed the decrease in <italic>B. hydrogenotrophica</italic> abundance observed in the placebo group of Pre-DM subjects (<italic>P</italic> &#x02264; 0.05) (Figure <xref ref-type="fig" rid="F4">4D</xref>).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>XOS selectively regulated some of the Pre-DM associated bacterial taxa in healthy subjects (<italic>n</italic> = 16) or Pre-DM subjects (<italic>n</italic> = 13) during 8 weeks</bold>. The abundances of Pre-DM associated <italic>Howardella</italic>
<bold>(A)</bold>, <italic>Slackia</italic>
<bold>(B)</bold>, and <italic>Enterorhabdus</italic>
<bold>(C)</bold> were greatly reduced by XOS in healthy and Pre-DM subjects, respectively. <bold>(D)</bold> The abundance of healthy associated <italic>Blautia hydrogenotrophica</italic> was enhanced by XOS in healthy and Pre-DM subjects. Values are presented as mean &#x000b1; standard error (SE) <sup>*</sup><italic>P</italic> &#x02264; 0.05.</p></caption><graphic xlink:href="fphys-06-00216-g0004"/></fig></sec><sec><title>Effects of XOS on body composition, metabolic, and immunological markers in Pre-DM subjects</title><p>In Pre-DM subjects, body composition, blood tests, and oral glucose tolerance tests (OGTT) were done at baseline and after 8 weeks of XOS intervention. Body weight and indexes of overall adiposity such as BMI, % fat, and % trunk fat were not changed by 8-week XOS intervention (Figure <xref ref-type="fig" rid="F5">5</xref>). Despite significant inter-individual variations in insulin responses among Pre-DM subjects, OGTT 2-h insulin response showed a tendency to decrease with XOS intervention in Pre-DM (<italic>P</italic> = 0.13) (Figure <xref ref-type="fig" rid="F6">6A</xref>). No significant XOS-related differences were observed in serum glucose, HOMA-IR, active GLP-1, triglycerides, leptin, PP, or the inflammatory marker TNF&#x003b1; (Figures <xref ref-type="fig" rid="F6">6B&#x02013;H</xref>).</p><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Body weight (A), BMI (B), % Fat (C), and % Trunk fat (D) in Pre-DM subjects at baseline and after 8 weeks placebo (<italic>n</italic> = 6) or XOS (<italic>n</italic> = 7) treatment</bold>. Data are means &#x000b1; standard errors (SE).</p></caption><graphic xlink:href="fphys-06-00216-g0005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><p><bold>Mean of parameters with SE at baseline and 8 weeks were compared between placebo- (<italic>n</italic> = 6) and XOS-treated (<italic>n</italic> = 7) group in Pre-DM subjects during the 120-min OGTT test. (A)</bold> Serum Insulin. <bold>(B)</bold> Serum glucose. <bold>(C)</bold> HOMA-IR. <bold>(D)</bold> Serum active GLP-1. <bold>(E)</bold> Serum triglyceride. <bold>(F)</bold> Serum pancreatic polypeptides. <bold>(G)</bold> Serum leptin. <bold>(H)</bold> Serum TNF &#x003b1;. Values are presented as mean &#x000b1; standard error (SE).</p></caption><graphic xlink:href="fphys-06-00216-g0006"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Emerging evidence suggests that metabolic disorders including T2DM are associated with a pro-inflammatory state secondary to dysbiosis of gut bacterial flora (Larsen et al., <xref rid="B25" ref-type="bibr">2010</xref>; Esteve et al., <xref rid="B14" ref-type="bibr">2011</xref>; Musso et al., <xref rid="B28" ref-type="bibr">2011</xref>). In addition, literature has documented the translocation of gut bacteria to blood and tissues in T2DM, and probiotic <italic>Bifidobacterium</italic> treatment prevents bacterial translocation and protects against T2DM (Cani et al., <xref rid="B8" ref-type="bibr">2007</xref>; Amar et al., <xref rid="B4" ref-type="bibr">2011</xref>). Together, these findings suggest that gut bacteria are an important modifier of T2DM.</p><p>The effects of oligosaccharides including XOS, FOS, and galactooligosaccharides (GOS) in the treatment of T2DM have gained interest. However, studies have shown inconsistent results. In T2DM patients, Yamashita et al. demonstrated that FOS at a dose of 8 g per day for 14 days resulted in a reduction of serum glucose, while Alles et al. showed that daily consumption of FOS at 15 g for 20 days had no effect on serum glucose level (Yamashita et al., <xref rid="B39" ref-type="bibr">1984</xref>; Alles et al., <xref rid="B3" ref-type="bibr">1999</xref>). Chan et al. showed that 4 g per day of XOS for 8 weeks was effective in reducing blood glucose and lipids in Taiwan T2DM patients (Sheu et al., <xref rid="B36" ref-type="bibr">2008</xref>), and for 21 days benefited intestinal health and increased of <italic>Bifidobacteria</italic> in elderly subjects (Chung et al., <xref rid="B11" ref-type="bibr">2007</xref>). Another study reported that both XOS and FOS dietary intervention reduced hyperglycaemia in diabetic rats (Gobinath et al., <xref rid="B18" ref-type="bibr">2010</xref>). In addition, we found that 2 g per day of XOS for 8 weeks increased the <italic>Bifidobacteria</italic> abundance in healthy Americans without any gastrointestinal side effects (Finegold et al., <xref rid="B17" ref-type="bibr">2014</xref>). Overall, a significant number of studies have shown oligosaccharides to be an effective option for lowering blood sugar in T2DM as well as improving intestinal health.</p><p>In the present study, both healthy and Pre-DM subjects were given 2 g per day of XOS for 8 weeks. Miseq sequencing was used to evaluate the potential of XOS in preventing the dysbiosis of gut microbiota during the development of T2DM. We found that XOS had a clear impact on gut microbiota in both healthy and Pre-DM groups, and resulted in dramatic shifts of several bacterial taxa associated with Pre-DM. Among them, <italic>Dialister spp</italic>. and <italic>Slackia</italic> are pro-inflammatory (Rocas and Siqueira, <xref rid="B33" ref-type="bibr">2006</xref>; Kim et al., <xref rid="B24" ref-type="bibr">2010</xref>), and were greatly reduced by XOS. Additionally, T2DM associated lactic acid bacteria <italic>Enterococcus, Streptococcus</italic>, and <italic>Lactobacillus</italic> (Remely et al., <xref rid="B32" ref-type="bibr">2013</xref>) were also greatly reduced by XOS. The inhibitory effect of XOS on other opportunistic pathogens, such as <italic>Clostridia, Streptococcaceae</italic>, and <italic>Subdoligranulum</italic>, further supports that XOS can potentially promote an optimal gut microbiota profile, and consequently reduce the risk of T2DM.</p><p>Miseq sequencing data also revealed that gut microbial composition of healthy subjects at different taxonomic levels was different from Pre-DM subjects. Some of our findings are consistent with previous T2DM studies of gut microflora (Qin et al., <xref rid="B31" ref-type="bibr">2012</xref>; Zhang et al., <xref rid="B40" ref-type="bibr">2013</xref>; Finegold et al., <xref rid="B17" ref-type="bibr">2014</xref>), substantiating the significant association of these changes with the progression of T2DM (Supplementary Table <xref ref-type="supplementary-material" rid="SM1">1</xref>). Studies showed that the <italic>Megamonas</italic> OTU was most enriched in Pre-DM, compared to healthy or T2DM individuals (Qin et al., <xref rid="B31" ref-type="bibr">2012</xref>; Zhang et al., <xref rid="B40" ref-type="bibr">2013</xref>). The abundance of <italic>Megamonas</italic> in our study was 200-fold higher in Pre-DM than healthy subjects. We also found that the abundance of the phylum <italic>Synergistetes</italic> in Pre-DM was about 50 fold higher compared with healthy subjects. The <italic>Synergistetes</italic> appear to be more numerous in individuals with oral-related diseases as well as gut and soft tissue infections (Vartoukian et al., <xref rid="B38" ref-type="bibr">2007</xref>). Another two infectious or metabolic disease related bacteria <italic>Eubacteriaceae</italic> (Plieskatt et al., <xref rid="B29" ref-type="bibr">2013</xref>) and <italic>Slackia</italic> (Kim et al., <xref rid="B24" ref-type="bibr">2010</xref>), were more abundant in Pre-DM individuals. The Pre-DM associated enrichment of infectious bacteria and the appearance of oral bacteria in the gut suggest that the host immune system may lose control over these opportunistic pathogens during the development of T2DM.</p><p>Both animal and clinical studies have shown that XOS supplementation greatly increases the <italic>Bifidobacterium</italic> population (Campbell et al., <xref rid="B7" ref-type="bibr">1997</xref>; Chung et al., <xref rid="B11" ref-type="bibr">2007</xref>; Finegold et al., <xref rid="B17" ref-type="bibr">2014</xref>). We previously showed that an increase of <italic>Bifidobacterium</italic> abundance was detectable only with an <italic>in vitro</italic> culture method, and not pyrosequencing (Finegold et al., <xref rid="B17" ref-type="bibr">2014</xref>). Using Miseq sequencing alone, the abundances of the <italic>Bifidobacterium</italic> genus, as well as the <italic>Bifidobacterium longum, Bifidobacterium bifidum</italic>, and <italic>Bifidobacterium adolescentis</italic> species were not significantly increased by XOS in healthy subjects (Supplementary Table <xref ref-type="supplementary-material" rid="SM1">4</xref>). However, we found that XOS largely inhibited bacterial taxa related to infectious and metabolic disease, such as family <italic>Streptococcaceae</italic>, class <italic>Clostridia</italic>, and genera <italic>Subdoligranulum, Gordonibacter</italic>, and <italic>Streptococcus</italic> in healthy subjects (Supplementary Table <xref ref-type="supplementary-material" rid="SM1">1</xref>). Furthermore, in healthy subjects, XOS greatly reduced the abundance of bacteria related to obesity or T2DM, including phylum <italic>Firmicutes</italic> and genera <italic>Subdoligranulum</italic> and <italic>Bacilli</italic> (Remely et al., <xref rid="B32" ref-type="bibr">2013</xref>; Zhang et al., <xref rid="B40" ref-type="bibr">2013</xref>). In Pre-DM subjects, XOS diminished or reversed the magnitude of population decline in about 70% bacterial taxa identified with a significant change from its baseline levels between treatment groups (Supplementary Table <xref ref-type="supplementary-material" rid="SM1">2</xref>). The family <italic>Veillonellaceae</italic> and genera <italic>Oscillospira</italic> and <italic>Dialister</italic> exhibited population declines in the placebo group, but demonstrated large increases in abundance in the XOS group. Abnormally low levels of <italic>Veillonellaceae</italic> and <italic>Dialister</italic> have been described in autistic children (Kang et al., <xref rid="B23" ref-type="bibr">2013</xref>) and patients of Crohn's disease (Joossens et al., <xref rid="B22" ref-type="bibr">2011</xref>). Dietary whole grain intervention (Martinez et al., <xref rid="B27" ref-type="bibr">2013</xref>) and corn fiber (Hooda et al., <xref rid="B20" ref-type="bibr">2012</xref>) increased the <italic>Dialister</italic> and <italic>Veillonellaceae</italic> abundance. The genus <italic>Oscillospira</italic> has been associated with lean BMI (Tims et al., <xref rid="B37" ref-type="bibr">2013</xref>). The inhibition of <italic>Firmicutes</italic> and increase of <italic>Oscillospira</italic> abundance suggest a potential role of XOS in weight control.</p><p>To the best of our knowledge, this is the first clinical study evaluating the effects of daily treatment with 2 g of XOS on glucose tolerance and insulin resistance in Pre-DM adults. In our experience, a dose of 2 g does not cause any gastrointestinal side effects (Finegold et al., <xref rid="B17" ref-type="bibr">2014</xref>). Eight weeks of XOS supplementation tended to increase insulin sensitivity by lowering OGTT 2-h insulin response (<italic>P</italic> = 0.11), while no significant improvement of Pre-DM subjects' metabolic situation was observed, using the parameters of body composition, serum glucose, triglyceride, satiety hormones and inflammation marker TNF&#x003b1;. The TNF&#x003b1; levels (4.91 &#x000b1; 1.85 pg/ml) of Pre-DM subjects in our study are normal, slightly lower than the reported TNF&#x003b1; (~15&#x02013;20 pg/ml) of eastern Indian Pre-DM population (Dutta et al., <xref rid="B13" ref-type="bibr">2013</xref>) and much lower than T2DM (range from 87 to 112 pg/ml) (Goyal et al., <xref rid="B19" ref-type="bibr">2012</xref>). Since we enrolled pre-DM subjects with impaired glucose tolerance (IGT) and without any other medical conditions we possibly did not observe elevated TNF&#x003b1; level. Pre-DM is a dynamic intermediate stage in the progression to T2DM, therefore it is very likely, subjects that met the selection criteria for Pre-DM are at different stages even though they are all classified as Pre-DM. Besides, studies also suggest a connection between TNF&#x003b1; gene polymorphism, its blood levels and the tendency to progression from Pre-DM to T2DM (Dutta et al., <xref rid="B13" ref-type="bibr">2013</xref>). Therefore, more studies are needed to improve our understanding of the relationship between TNA&#x003b1;, Pre-DM staging, and T2DM progression. Our results do not agree with Chan et al. study in T2DM. However, this discrepancy could be explained by difference in XOS dose, study population and disease stages. It is possible that 2 g per day of XOS may have been too low to induce a difference in glucose tolerance. However, we observed a trend of increased insulin sensitivity by lowering OGTT 2-h insulin response at this dosage. Pre-DM is a strong risk factor for the development of T2DM, and the regulation of glucose metabolism and insulin sensitivity could be really dynamic during this stage. We think future clinical study with large sample size will be needed to confirm the benefits of XOS in Pre-DM.</p><p>In conclusion, XOS significantly modified gut microbiota in both healthy and Pre-DM subjects, and resulted in dramatic shifts of 4 bacterial taxa associated with Pre-DM. Future studies with larger sample size are needed to study the metabolic impact of XOS and understand the connection between XOS-mediated gut microbiota changes and the pathogenesis of T2DM.</p></sec><sec id="s5"><title>Source of support</title><p>Supported by departmental funds from the Center for Human Nutrition, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>ZL and DH designed research and had primary responsibility for final content. SH, JY, MH, HM, JH, PS, and G. Thames conducted research. SF, CT, and JY analyzed the data. JY wrote paper.</p></ack><sec sec-type="supplementary-material" id="s6"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="http://journal.frontiersin.org/article/10.3389/fphys.2015.00216">http://journal.frontiersin.org/article/10.3389/fphys.2015.00216</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="DataSheet1.DOC"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aachary</surname><given-names>A. A.</given-names></name><name><surname>Prapulla</surname><given-names>S. G.</given-names></name></person-group> (<year>2011</year>). <article-title>Xylooligosaccharides (XOS) as an emerging prebiotic: microbial synthesis, utilization, structural characterization, bioactive properties, and applications</article-title>. <source>Compr. Rev. Food Sci. Food Saf.</source>
<volume>10</volume>, <fpage>2</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1111/j.1541-4337.2010.00135.x</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allard</surname><given-names>P.</given-names></name><name><surname>Delvin</surname><given-names>E. E.</given-names></name><name><surname>Paradis</surname><given-names>G.</given-names></name><name><surname>Hanley</surname><given-names>J. A.</given-names></name><name><surname>O'Loughlin</surname><given-names>J.</given-names></name><name><surname>Lavall&#x000e9;e</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Distribution of fasting plasma insulin, free fatty acids, and glucose concentrations and of homeostasis model assessment of insulin resistance in a representative sample of Quebec children and adolescents</article-title>. <source>Clin. Chem.</source>
<volume>49</volume>, <fpage>644</fpage>&#x02013;<lpage>649</lpage>. <pub-id pub-id-type="doi">10.1373/49.4.644</pub-id><pub-id pub-id-type="pmid">12651818</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alles</surname><given-names>M. S.</given-names></name><name><surname>de Roos</surname><given-names>N. M.</given-names></name><name><surname>Bakx</surname><given-names>J. C.</given-names></name><name><surname>van de Lisdonk</surname><given-names>E.</given-names></name><name><surname>Zock</surname><given-names>P. L.</given-names></name><name><surname>Hautvast</surname><given-names>G. A.</given-names></name></person-group> (<year>1999</year>). <article-title>Consumption of fructooligosaccharides does not favorably affect blood glucose and serum lipid concentrations in patients with type 2 diabetes</article-title>. <source>Am. J. Clin. Nutr.</source>
<volume>69</volume>, <fpage>64</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="pmid">9925124</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amar</surname><given-names>J.</given-names></name><name><surname>Chabo</surname><given-names>C.</given-names></name><name><surname>Waget</surname><given-names>A.</given-names></name><name><surname>Klopp</surname><given-names>P.</given-names></name><name><surname>Vachoux</surname><given-names>C.</given-names></name><name><surname>Berm&#x000fa;dez-Humar&#x000e1;n</surname><given-names>L. G.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment</article-title>. <source>EMBO Mol. Med.</source>
<volume>3</volume>, <fpage>559</fpage>&#x02013;<lpage>572</lpage>. <pub-id pub-id-type="doi">10.1002/emmm.201100159</pub-id><pub-id pub-id-type="pmid">21735552</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group> (<year>2014</year>). <article-title>Standards of medical care in diabetes&#x02013;2014.</article-title>
<source>Diabetes Care</source>
<volume>37</volume>(<issue>Suppl. 1</issue>), <fpage>S14</fpage>&#x02013;<lpage>S80</lpage>. <pub-id pub-id-type="doi">10.2337/dc14-S014</pub-id><pub-id pub-id-type="pmid">24357209</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumgartner</surname><given-names>A.</given-names></name><name><surname>Thurnheer</surname><given-names>T.</given-names></name><name><surname>L&#x000fc;thi-Schaller</surname><given-names>H.</given-names></name><name><surname>Gm&#x000fc;r</surname><given-names>R.</given-names></name><name><surname>Belibasakis</surname><given-names>G. N.</given-names></name></person-group> (<year>2012</year>). <article-title>The phylum Synergistetes in gingivitis and necrotizing ulcerative gingivitis</article-title>. <source>J. Med. Microbiol</source>. <volume>61(Pt 11)</volume>, <fpage>1600</fpage>&#x02013;<lpage>1609</lpage>. <pub-id pub-id-type="doi">10.1099/jmm.0.047456-0</pub-id><pub-id pub-id-type="pmid">22878253</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>J. M.</given-names></name><name><surname>Fahey</surname><given-names>G. C.</given-names><suffix>Jr.</suffix></name><name><surname>Wolf</surname><given-names>B. W.</given-names></name></person-group> (<year>1997</year>). <article-title>Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats</article-title>. <source>J. Nutr.</source>
<volume>127</volume>, <fpage>130</fpage>&#x02013;<lpage>136</lpage>. <pub-id pub-id-type="pmid">9040556</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cani</surname><given-names>P. D.</given-names></name><name><surname>Neyrinck</surname><given-names>A. M.</given-names></name><name><surname>Fava</surname><given-names>F.</given-names></name><name><surname>Knauf</surname><given-names>C.</given-names></name><name><surname>Burcelin</surname><given-names>R. G.</given-names></name><name><surname>Tuohy</surname><given-names>K. M.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia</article-title>. <source>Diabetologia</source>
<volume>50</volume>, <fpage>2374</fpage>&#x02013;<lpage>2383</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-007-0791-0</pub-id><pub-id pub-id-type="pmid">17823788</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chassaing</surname><given-names>B.</given-names></name><name><surname>Gewirtz</surname><given-names>A. T.</given-names></name></person-group> (<year>2014</year>). <article-title>Gut microbiota, low-grade inflammation, and metabolic syndrome</article-title>. <source>Toxicol. Pathol.</source>
<volume>42</volume>, <fpage>49</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1177/0192623313508481</pub-id><pub-id pub-id-type="pmid">24285672</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>N.</given-names></name><name><surname>Shin</surname><given-names>H. S.</given-names></name></person-group> (<year>2006</year>). <article-title>Effect of oligosaccharides and inulin on the growth and viability of bifidobacteria in skim milk</article-title>. <source>Food Sci. Biotechnol.</source>
<volume>15</volume>, <fpage>543</fpage>&#x02013;<lpage>548</lpage>.</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>Y. C.</given-names></name><name><surname>Hsu</surname><given-names>C. K.</given-names></name><name><surname>Ko</surname><given-names>C. Y.</given-names></name><name><surname>Chan</surname><given-names>Y. C.</given-names></name></person-group> (<year>2007</year>). <article-title>Dietary intake of xylooligosaccharides improves the intestinal microbiota, fecal moisture, and pH value in the elderly</article-title>. <source>Nutr. Res.</source>
<volume>27</volume>, <fpage>756</fpage>&#x02013;<lpage>761</lpage>. <pub-id pub-id-type="doi">10.1016/j.nutres.2007.09.014</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeSantis</surname><given-names>T. Z.</given-names></name><name><surname>Hugenholtz</surname><given-names>P.</given-names></name><name><surname>Larsen</surname><given-names>N.</given-names></name><name><surname>Rojas</surname><given-names>M.</given-names></name><name><surname>Brodie</surname><given-names>E. L.</given-names></name><name><surname>Keller</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB</article-title>. <source>Appl. Environ. Microbiol.</source>
<volume>72</volume>, <fpage>5069</fpage>&#x02013;<lpage>5072</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.03006-05</pub-id><pub-id pub-id-type="pmid">16820507</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>D.</given-names></name><name><surname>Choudhuri</surname><given-names>S.</given-names></name><name><surname>Mondal</surname><given-names>S. A.</given-names></name><name><surname>Maisnam</surname><given-names>I.</given-names></name><name><surname>Reza</surname><given-names>A. H.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Tumor necrosis factor alpha -238G/A (rs 361525) gene polymorphism predicts progression to type-2 diabetes in an Eastern Indian population with prediabetes</article-title>. <source>Diab. Res. Clin. Pract.</source>
<volume>99</volume>, <fpage>e37</fpage>&#x02013;<lpage>e41</lpage>. <pub-id pub-id-type="doi">10.1016/j.diabres.2012.12.007</pub-id><pub-id pub-id-type="pmid">23298660</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esteve</surname><given-names>E.</given-names></name><name><surname>Ricart</surname><given-names>W.</given-names></name><name><surname>Fern&#x000e1;ndez-Real</surname><given-names>J. M.</given-names></name></person-group> (<year>2011</year>). <article-title>Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance?</article-title>
<source>Curr. Opin. Clin. Nutr. Metab. Care</source>
<volume>14</volume>, <fpage>483</fpage>&#x02013;<lpage>490</lpage>. <pub-id pub-id-type="doi">10.1097/mco.0b013e328348c06d</pub-id><pub-id pub-id-type="pmid">21681087</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everard</surname><given-names>A.</given-names></name><name><surname>Belzer</surname><given-names>C.</given-names></name><name><surname>Geurts</surname><given-names>L.</given-names></name><name><surname>Ouwerkerk</surname><given-names>J. P.</given-names></name><name><surname>Druart</surname><given-names>C.</given-names></name><name><surname>Bindels</surname><given-names>L. B.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Cross-talk between <italic>Akkermansia muciniphila</italic> and intestinal epithelium controls diet-induced obesity</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>110</volume>, <fpage>9066</fpage>&#x02013;<lpage>9071</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1219451110</pub-id><pub-id pub-id-type="pmid">23671105</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everard</surname><given-names>A.</given-names></name><name><surname>Lazarevic</surname><given-names>V.</given-names></name><name><surname>Derrien</surname><given-names>M.</given-names></name><name><surname>Girard</surname><given-names>M.</given-names></name><name><surname>Muccioli</surname><given-names>G. G.</given-names></name><name><surname>Neyrinck</surname><given-names>A. M.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice</article-title>. <source>Diabetes</source>
<volume>60</volume>, <fpage>2775</fpage>&#x02013;<lpage>2786</lpage>. <pub-id pub-id-type="doi">10.2337/db11-0227</pub-id><pub-id pub-id-type="pmid">21933985</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finegold</surname><given-names>S. M.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Summanen</surname><given-names>P. H.</given-names></name><name><surname>Downes</surname><given-names>J.</given-names></name><name><surname>Thames</surname><given-names>G.</given-names></name><name><surname>Corbett</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota</article-title>. <source>Food Funct.</source>
<volume>5</volume>, <fpage>436</fpage>&#x02013;<lpage>445</lpage>. <pub-id pub-id-type="doi">10.1039/c3fo60348b</pub-id><pub-id pub-id-type="pmid">24513849</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gobinath</surname><given-names>D.</given-names></name><name><surname>Madhu</surname><given-names>A. N.</given-names></name><name><surname>Prashant</surname><given-names>G.</given-names></name><name><surname>Srinivasan</surname><given-names>K.</given-names></name><name><surname>Prapulla</surname><given-names>S. G.</given-names></name></person-group> (<year>2010</year>). <article-title>Beneficial effect of xylo-oligosaccharides and fructo-oligosaccharides in streptozotocin-induced diabetic rats</article-title>. <source>Br. J. Nutr.</source>
<volume>104</volume>, <fpage>40</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1017/S0007114510000243</pub-id><pub-id pub-id-type="pmid">20187988</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>R.</given-names></name><name><surname>Faizy</surname><given-names>A. F.</given-names></name><name><surname>Siddiqui</surname><given-names>S. S.</given-names></name><name><surname>Singhai</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Evaluation of TNF-alpha and IL-6 levels in obese and non-obese diabetics: pre- and postinsulin effects</article-title>. <source>N. Am. J. Med. Sci.</source>
<volume>4</volume>, <fpage>180</fpage>&#x02013;<lpage>184</lpage>. <pub-id pub-id-type="doi">10.4103/1947-2714.94944</pub-id><pub-id pub-id-type="pmid">22536561</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooda</surname><given-names>S.</given-names></name><name><surname>Boler</surname><given-names>B. M. V.</given-names></name><name><surname>Serao</surname><given-names>M. C. R.</given-names></name><name><surname>Brulc</surname><given-names>J. M.</given-names></name><name><surname>Staeger</surname><given-names>M. A.</given-names></name><name><surname>Boileau</surname><given-names>T. W.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>454 pyrosequencing reveals a shift in fecal microbiota of healthy adult men consuming polydextrose or soluble corn fiber</article-title>. <source>J. Nutr.</source>
<volume>142</volume>, <fpage>1259</fpage>&#x02013;<lpage>1265</lpage>. <pub-id pub-id-type="doi">10.3945/jn.112.158766</pub-id><pub-id pub-id-type="pmid">22649263</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>International Scientific Association for Probiotics Prebiotics</collab></person-group>. (<year>2004</year>). <article-title>Probiotics, prebiotics, and new foods. Proceedings of the 2nd annual meeting. Rome, Italy, September 7&#x02013;9, 2003.</article-title>
<source>J. Clin. Gastroenterol.</source>
<volume>38</volume>(<issue>6 Suppl</issue>.), <fpage>S60</fpage>&#x02013;<lpage>S129</lpage>. <pub-id pub-id-type="pmid">15220659</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joossens</surname><given-names>M.</given-names></name><name><surname>Huys</surname><given-names>G.</given-names></name><name><surname>Cnockaert</surname><given-names>M.</given-names></name><name><surname>De Preter</surname><given-names>V.</given-names></name><name><surname>Verbeke</surname><given-names>K.</given-names></name><name><surname>Rutgeerts</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives</article-title>. <source>Gut</source>
<volume>60</volume>, <fpage>631</fpage>&#x02013;<lpage>637</lpage>. <pub-id pub-id-type="doi">10.1136/gut.2010.223263</pub-id><pub-id pub-id-type="pmid">21209126</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>D. W.</given-names></name><name><surname>Park</surname><given-names>J. G.</given-names></name><name><surname>Ilhan</surname><given-names>Z. E.</given-names></name><name><surname>Wallstrom</surname><given-names>G.</given-names></name><name><surname>Labaer</surname><given-names>J.</given-names></name><name><surname>Adams</surname><given-names>J. B.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children</article-title>. <source>PLoS ONE</source>
<volume>8</volume>:<fpage>e68322</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0068322</pub-id><pub-id pub-id-type="pmid">23844187</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K. S.</given-names></name><name><surname>Rowlinson</surname><given-names>M. C.</given-names></name><name><surname>Bennion</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Talan</surname><given-names>D.</given-names></name><name><surname>Summanen</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Characterization of Slackia exigua isolated from human wound infections, including abscesses of intestinal origin</article-title>. <source>J. Clin. Microbiol.</source>
<volume>48</volume>, <fpage>1070</fpage>&#x02013;<lpage>1075</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.01576-09</pub-id><pub-id pub-id-type="pmid">20107092</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>N.</given-names></name><name><surname>Vogensen</surname><given-names>F. K.</given-names></name><name><surname>van den Berg</surname><given-names>F. W.</given-names></name><name><surname>Nielsen</surname><given-names>D. S.</given-names></name><name><surname>Andreasen</surname><given-names>A. S.</given-names></name><name><surname>Pedersen</surname><given-names>B. K.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults</article-title>. <source>PLoS ONE</source>
<volume>5</volume>:<fpage>e9085</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0009085</pub-id><pub-id pub-id-type="pmid">20140211</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marotti</surname><given-names>I.</given-names></name><name><surname>Bregola</surname><given-names>V.</given-names></name><name><surname>Aloisio</surname><given-names>I.</given-names></name><name><surname>Di Gioia</surname><given-names>D.</given-names></name><name><surname>Bosi</surname><given-names>S.</given-names></name><name><surname>Di Silvestro</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Prebiotic effect of soluble fibres from modern and old durum-type wheat varieties on Lactobacillus and Bifidobacterium strains</article-title>. <source>J. Sci. Food Agric.</source>
<volume>92</volume>, <fpage>2133</fpage>&#x02013;<lpage>2140</lpage>. <pub-id pub-id-type="doi">10.1002/jsfa.5597</pub-id><pub-id pub-id-type="pmid">22298124</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez</surname><given-names>I.</given-names></name><name><surname>Lattimer</surname><given-names>J. M.</given-names></name><name><surname>Hubach</surname><given-names>K. L.</given-names></name><name><surname>Case</surname><given-names>J. A.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Weber</surname><given-names>C. G.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Gut microbiome composition is linked to whole grain-induced immunological improvements</article-title>. <source>ISME J.</source>
<volume>7</volume>, <fpage>269</fpage>&#x02013;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1038/ismej.2012.104</pub-id><pub-id pub-id-type="pmid">23038174</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musso</surname><given-names>G.</given-names></name><name><surname>Gambino</surname><given-names>R.</given-names></name><name><surname>Cassader</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes</article-title>. <source>Annu. Rev. Med.</source>
<volume>62</volume>, <fpage>361</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-med-012510-175505</pub-id><pub-id pub-id-type="pmid">21226616</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plieskatt</surname><given-names>J. L.</given-names></name><name><surname>Deenonpoe</surname><given-names>R.</given-names></name><name><surname>Mulvenna</surname><given-names>J. P.</given-names></name><name><surname>Krause</surname><given-names>L.</given-names></name><name><surname>Sripa</surname><given-names>B.</given-names></name><name><surname>Bethony</surname><given-names>J. M.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Infection with the carcinogenic liver fluke Opisthorchis viverrini modifies intestinal and biliary microbiome</article-title>. <source>Faseb J.</source>
<volume>27</volume>, <fpage>4572</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1096/fj.13-232751</pub-id><pub-id pub-id-type="pmid">23925654</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portero McLellan</surname><given-names>K. C.</given-names></name><name><surname>Wyne</surname><given-names>K.</given-names></name><name><surname>Villagomez</surname><given-names>E. T.</given-names></name><name><surname>Hsueh</surname><given-names>W. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus</article-title>. <source>Ther. Clin. Risk Manag.</source>
<volume>10</volume>, <fpage>173</fpage>&#x02013;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.2147/TCRM.S39564</pub-id><pub-id pub-id-type="pmid">24672242</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Cai</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>A metagenome-wide association study of gut microbiota in type 2 diabetes</article-title>. <source>Nature</source>
<volume>490</volume>, <fpage>55</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1038/nature11450</pub-id><pub-id pub-id-type="pmid">23023125</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remely</surname><given-names>M.</given-names></name><name><surname>Dworzak</surname><given-names>S.</given-names></name><name><surname>Hippe</surname><given-names>B.</given-names></name><name><surname>Zwielehner</surname><given-names>J.</given-names></name><name><surname>Aum&#x000fc;ller</surname><given-names>E.</given-names></name><name><surname>Brath</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Abundance and diversity of microbiota in type 2 diabetes and obesity</article-title>. <source>J. Diab. Metab.</source>
<volume>4</volume>:<fpage>253</fpage>
<pub-id pub-id-type="doi">10.4172/2155-6156.1000253</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocas</surname><given-names>I. N.</given-names></name><name><surname>Siqueira</surname><given-names>J. F.</given-names><suffix>Jr.</suffix></name></person-group> (<year>2006</year>). <article-title>Characterization of Dialister species in infected root canals</article-title>. <source>J. Endod.</source>
<volume>32</volume>, <fpage>1057</fpage>&#x02013;<lpage>1061</lpage>. <pub-id pub-id-type="doi">10.1016/j.joen.2006.04.010</pub-id><pub-id pub-id-type="pmid">17055906</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>M.</given-names></name><name><surname>Corradini</surname><given-names>C.</given-names></name><name><surname>Amaretti</surname><given-names>A.</given-names></name><name><surname>Nicolini</surname><given-names>M.</given-names></name><name><surname>Pompei</surname><given-names>A.</given-names></name><name><surname>Zanoni</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Fermentation of fructooligosaccharides and inulin by bifidobacteria: a comparative study of pure and fecal cultures</article-title>. <source>Appl. Environ. Microbiol.</source>
<volume>71</volume>, <fpage>6150</fpage>&#x02013;<lpage>6158</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.71.10.6150-6158.2005</pub-id><pub-id pub-id-type="pmid">16204533</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Obin</surname><given-names>M. S.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name></person-group> (<year>2013</year>). <article-title>The gut microbiota, obesity and insulin resistance</article-title>. <source>Mol. Aspects Med.</source>
<volume>34</volume>, <fpage>39</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2012.11.001</pub-id><pub-id pub-id-type="pmid">23159341</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sheu</surname><given-names>W. H.</given-names></name><name><surname>Lee</surname><given-names>I. T.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Chan</surname><given-names>Y. C.</given-names></name></person-group> (<year>2008</year>). <article-title>Effects of xylooligosaccharides in type 2 diabetes mellitus</article-title>. <source>J. Nutr. Sci. Vitaminol.</source> (<publisher-loc>Tokyo</publisher-loc>) <volume>54</volume>, <fpage>396</fpage>&#x02013;<lpage>401</lpage>. <pub-id pub-id-type="doi">10.3177/jnsv.54.396</pub-id><pub-id pub-id-type="pmid">19001772</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tims</surname><given-names>S.</given-names></name><name><surname>Derom</surname><given-names>C.</given-names></name><name><surname>Jonkers</surname><given-names>D. M.</given-names></name><name><surname>Vlietinck</surname><given-names>R.</given-names></name><name><surname>Saris</surname><given-names>W. H.</given-names></name><name><surname>Kleerebezem</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Microbiota conservation and BMI signatures in adult monozygotic twins</article-title>. <source>ISME J.</source>
<volume>7</volume>, <fpage>707</fpage>&#x02013;<lpage>717</lpage>. <pub-id pub-id-type="doi">10.1038/ismej.2012.146</pub-id><pub-id pub-id-type="pmid">23190729</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vartoukian</surname><given-names>S. R.</given-names></name><name><surname>Palmer</surname><given-names>R. M.</given-names></name><name><surname>Wade</surname><given-names>W. G.</given-names></name></person-group> (<year>2007</year>). <article-title>The division &#x0201c;Synergistes&#x0201d;</article-title>. <source>Anaerobe</source>
<volume>13</volume>, <fpage>99</fpage>&#x02013;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/j.anaerobe.2007.05.004</pub-id><pub-id pub-id-type="pmid">17631395</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>K.</given-names></name><name><surname>Kawai</surname><given-names>K.</given-names></name><name><surname>Itakura</surname><given-names>M.</given-names></name></person-group> (<year>1984</year>). <article-title>Effects of fructo-oligosaccharides on blood-glucose and serum-lipids in diabetic subjects</article-title>. <source>Nutr. Res.</source>
<volume>4</volume>, <fpage>961</fpage>&#x02013;<lpage>966</lpage>. <pub-id pub-id-type="doi">10.1016/S0271-5317(84)80075-5</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Shen</surname><given-names>D.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Jie</surname><given-names>Z.</given-names></name><name><surname>Qiu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Human gut microbiota changes reveal the progression of glucose intolerance</article-title>. <source>PLoS ONE</source>
<volume>8</volume>:<fpage>e71108</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0071108</pub-id><pub-id pub-id-type="pmid">24013136</pub-id></mixed-citation></ref></ref-list><glossary><def-list><title>Abbreviations</title><def-item><term>XOS</term><def><p>xylooligosaccharide</p></def></def-item><def-item><term>Pre-DM</term><def><p>prediabetic</p></def></def-item><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>T2DM</term><def><p>Type 2 Diabetes Mellitus</p></def></def-item><def-item><term>FOS</term><def><p>fructooligosaccharides</p></def></def-item><def-item><term>GOS</term><def><p>galactooligosaccharides</p></def></def-item><def-item><term>OGTT</term><def><p>oral glucose tolerance test</p></def></def-item></def-list></glossary></back></article>